Nutrition
Nutrition

Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice

By Dr. Elena Voss ·

Microglial Activation: The Key to Tau Clearance

A recent study shows that the BCG vaccine, traditionally used against tuberculosis, can lower tau protein buildup in the brains of mice. The research, conducted in a laboratory setting, suggests a potential new avenue for dementia prevention in humans.

The experiment involved mice genetically engineered to develop tau tangles, a hallmark of Alzheimer’s disease. Researchers administered the BCG vaccine and observed a significant reduction in tau aggregates. The effect is attributed to enhanced activity of microglial cells, the brain’s resident immune cells, which appear to clear tau more efficiently after vaccination.

Microglia are crucial for maintaining neural health by removing waste and damaged proteins. In the study, BCG vaccination triggered a surge in microglial activation. These cells increased their phagocytic capacity, engulfing and degrading tau tangles that normally accumulate in diseased brains. The researchers measured a 30‑40% drop in tau levels compared to untreated mice, indicating a robust therapeutic response.

Could BCG Reduce Dementia Risk in Humans?

The team also noted changes in inflammatory signaling pathways. BCG is known to stimulate the immune system, and this heightened immune tone seems to create a more favorable environment for microglia to function. By modulating cytokine profiles, the vaccine may reduce chronic inflammation that otherwise hampers protein clearance.

The findings raise the question: can a tuberculosis vaccine help prevent or slow dementia in people? Retrospective analyses of bladder cancer patients treated with BCG have reported lower rates of neurodegenerative disease, hinting at a protective effect. However, translating results from mice to humans requires caution. Human brains are more complex, and the timing, dosage, and long‑term safety of BCG for this purpose remain unknown.

Future clinical trials will need to address whether BCG can safely cross the blood‑brain barrier in older adults, and whether repeated doses are necessary. Researchers are also exploring whether other vaccines that activate innate immunity could offer similar benefits.

The potential impact is significant. If BCG or similar immunotherapies can reduce tau pathology, they could complement existing drug development efforts and offer a low‑cost, widely available intervention. This could shift the focus from treating symptoms to modifying disease progression.

Frequently Asked Questions

What is tau protein, and why is it important in dementia? Tau is a protein that stabilizes microtubules in neurons. In Alzheimer’s disease, abnormal tau forms tangles that disrupt cell function and lead to cell death.

How does BCG vaccination influence microglial cells? BCG stimulates the immune system, increasing microglial activation and their ability to phagocytose, or engulf, tau aggregates in the brain.

Are there plans for human trials of BCG for dementia prevention? Researchers are proposing early‑phase studies to assess safety and efficacy in older adults, but no definitive trial dates have been announced yet.